Search Results

BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company utilizing a powerful TCR discovery platform to identify novel therapeutic candidates for patients with hematologic malignancies and solid tumors, today announced a strategic collaboration with the National Cancer Institute (NCI), part of the National Institutes of Health.

ATCC will continue to support the National Cancer Institute’s (NCI) mission to prevent cancer and the Division of Cancer Epidemiology and Genetics (DCEG) Biospecimen Activity and Assay Support (BAAS) program.

Chimeron Bio, a Philadelphia -headquartered biotech company, has received a 2024 National Institutes of Health’s Small Business Innovation Research Innovative Concept Award through the National Cancer Institute.

BostonGene Announces Publication in Collaboration with National Cancer Institute and National Institute of Allergy and Infectious Diseases in Cancer Cell.

Xylyx Bio, Inc. announced that it has been awarded a Small Business Innovation Research Fast-Track grant from the National Cancer Institute of the National Institutes of Health to advance commercial development of its InMatrico® disease modeling and drug testing platform to help scientists discover and test drug candidates for metastatic breast cancer.

LIXTE Biotechnology Holdings, Inc. ( Nasdaq: LIXT and LIXTW ) (“LIXTE” or the “Company”) today announced the signing of an exclusive patent license agreement with the National Institute of Neurological Disorders and Stroke (NINDS) and National Cancer Institute (NCI), each a component of the National Institute of Health (NIH).